Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed ERapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83%
Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed ERapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83%
Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed ERapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Months
Biodexa Pharmicals公布了其新授权的家族性腺瘤性息肉eRapa的2期临床试验结果，该结果计划在2024年消化系统疾病周年会上公布；报告称，6个月的总体非进展率为83％
Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Biodexa Pricals
（“Biodexa” 或 “公司”）
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting. Overall 83% non-progression rate at 6 Months. Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04)
Biodexa新获得许可的eRapa治疗家族性腺瘤性息肉病（FAP）的2期临床试验结果具有统计学意义，该结果计划在2024年消化系统疾病周年会上公布。6个月的总体非进展率为83％。从统计学上讲，6个月时息肉总负担显著降低（p=0.04）
Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that results of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") (NCT04230499) are scheduled for presentation at the prestigious 2024 Digestive Disease Week annual meeting in Washington D.C.. Carol Burke, MD, the Principal Investigator, will present the six month data in a podium presentation at the meeting.
Biodexa Pharmicals PLC（纳斯达克股票代码：BDRX）是一家专注于收购的临床阶段生物制药公司，正在开发一系列用于治疗医疗需求未得到满足的疾病的创新产品。该公司很高兴地宣布，eRapa治疗家族性腺瘤性息肉（“FAP”）（NCT04230499）的2期临床试验结果计划在华盛顿特区久负盛名的2024年消化疾病周年会上公布。首席研究员卡罗尔·伯克医学博士将在会议的讲台上介绍六个月的数据。
The study was partially supported by $20M in grant funding from the Cancer Prevention and Research Institute of Texas under product development awards DP22053 and DP190069.
该研究得到了德克萨斯州癌症预防与研究所在 DP22053 和 DP190069 产品开发奖项下提供的2000万美元拨款的部分支持。
译文内容由第三方软件翻译。